Health

STAT+: Pharmalittle: We’re reading about 340B battles, new results for a Lilly weight loss drug, and more

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 28/10/2026, 13:51:24 UTC.

Briefings

STAT reported on a new FDA draft guidance streamlining approvals for individualized gene therapies targeting rare diseases, while simultaneously noting Missouri Attorney General Catherine Hanaway's enforcement action against Eli Lilly for violating the 340B Drug Pricing Program. The article highlights a conflict between federal regulatory changes and state-level enforcement of drug pricing laws.

Key points

• The U.S. Food and Drug Administration published draft guidance to streamline approvals for individualized gene therapies targeting rare diseases.
• Missouri Attorney General Catherine Hanaway issued a cease-and-desist letter to Eli Lilly for violating the 340B Drug Pricing Program.

Context

STAT+ reports on regulatory shifts in gene therapy approvals and state enforcement actions against pharmaceutical companies regarding drug pricing programs.

Limitations

Evidence covers only FDA guidance and Missouri Attorney General's enforcement action; no data on other states, specific gene therapy applications, or Lilly's full compliance history is provided.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 29/10/2026, 06:31:14 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeifcamzlmnzprnggfqlkznoclklygslssncrwq5ki5q2utciipdk5a